Low and Mighty: How Low-Affinity Antibodies Boost Cancer Immunotherapy

Authors

DOI:

https://doi.org/10.25250/thescbr.brk740

Keywords:

cancer immunotherapy, Immunology, cancer, antibodies, structural biology

Abstract

Antibodies, nature’s guided missiles, are designed to bind to their targets with high precision. The tighter they bind, the better they’re thought to perform. But what if we’ve been wrong all this time? Our research suggests that antibodies with a looser grip can sometimes be more effective. This unexpected finding could open new avenues for improved antibody-based therapies.

Author Biographies

Christian M. Orr, Diamond Light Source

Beamline Scientist

Chelsea S. Norman, Rosalind Franklin Institute

Senior Laboratory Technician

Mark S. Cragg, University of Southampton

Professor

Original article reference

Yu, X., Orr, C.M., Chan, H.T.C. et al. Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature 614, 539–547 (2023).

Downloads

  • URL

Published

2023-09-01

Issue

Vol. 9 No. 3 (2023): TheScienceBreaker

Section

Health & Physiology

License

Some rights reserved 2023 Christian M. Orr, Chelsea S. Norman, Mark S. Cragg

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.